The gut microbiome, mild cognitive impairment, and probiotics: A randomized clinical trial in middle-aged and older adults

Coming Soon.

Year: 2022

Reference: Aljumaah, M. R., Bhatia, U., Roach, J., Gunstad, J., & Azcarate Peril, M. A. (2022). The gut microbiome, mild cognitive impairment, and probiotics: A randomized clinical trial in middle-aged and older adults. Clinical nutrition (Edinburgh, Scotland), 41(11), 2565–2576. https://doi.org/10.1016/j.clnu.2022.09.012

Related Studies

Gut microbiota in depression: A focus on ketamine

This 2021 study discusses the antidepressant effect of ketamine and its effectiveness in treatment-resistant depression. Around 30% of depressive patients are said to be resistant to treatment, which implies that there are not enough effective treatments for depression. The gut microbiome is increasingly recognized as an influential factor in depression, seemingly acting through the gut-microbiota-brain […]

The gut microbiota-immune-brain axis: Therapeutic implications

Role of the Microbiota-Gut-Brain Axis in Human Health Human health is greatly impacted by the microbiota-gut-brain axis, which affects behavior, brain activity, and gastrointestinal function. A key communication pathway within this axis is the immune system, which connects the gut microbiome to neuroinflammatory processes in both health and disease. Findings from Recent Review on Gut-Brain-Immune […]